← Eichor
Study identifier: NCT05113368 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Condition: Ovarian Cancer · Serous Ovarian Cancer  ·  Sponsor: Sarah K. Lynam MD

PhasePhase 2
Planned participants31
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Sarah Lynam, MD  ·  1-800-641-2422  ·  Sarah.Lynam@UHhospitals.org

Nancy Fusco, RN  ·  216-844-3954  ·  nancy.fusco@UHhospitals.org

Always discuss trial participation with your own doctor first.

Locations (1)

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer CenterCleveland, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05113368